Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers
In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...
News-Medical.Net on MSN5h
FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...
Mirage News8h
FGFR2 Targeting May Halt KRAS-Mutant Pancreatic Cancer
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...
Physician's Weekly1d
Distinct Clinical and Treatment Profiles of KRAS G12D and G12C in NSCLC
World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March ...
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...
Science Daily5h
In pancreatic cancer, a race against time
Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...
CURE4h
The Benefit of Clinical Trial Enrollment for Patients With Cancer
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...
SEBI extends cybersecurity framework deadline once more for all except MIIs, KRAs & QRTAs
The market regulator has once again extended the deadline for registered entities (REs) to adopt Cybersecurity and Cyber ...
Medical Xpress on MSN14d
KRAS Genetic Mutation Linked to Poor Prognosis in Pancreatic Cancer
A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — ...
Edible garden targets profitability in 2025 with expanded product focus and improved margins
Discover key insights from Edible Garden's Q4 2024 earnings call, highlighting 181.3% profit growth, strategic shifts, and plans for global expansion in 2025.